1415303-41-1 Usage
Uses
Used in Pharmaceutical Synthesis:
(R)-1-(6-bromopyridin-2-yl)ethan-1-amine hydrochloride is used as an intermediate in the pharmaceutical industry for the production of potential drug candidates. Its unique structure allows it to be a key component in the development of new medications, contributing to the advancement of therapeutic options.
Used in Agrochemical Production:
In the agrochemical sector, (R)-1-(6-bromopyridin-2-yl)ethan-1-amine hydrochloride serves as an intermediate for the synthesis of compounds with pesticidal or herbicidal properties. Its role in this industry is crucial for the development of effective and environmentally friendly solutions for agricultural challenges.
Used in Chemical Research and Development:
(R)-1-(6-bromopyridin-2-yl)ethan-1-amine hydrochloride is also utilized as a building block in chemical research and development. Its versatility in forming new molecules with potential pharmacological activity makes it a valuable asset in the creation of innovative chemical entities for various applications.
The hydrochloride salt form of this compound enhances its solubility and stability, which is essential for its successful integration into the processes and products of the pharmaceutical and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1415303-41-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,5,3,0 and 3 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1415303-41:
(9*1)+(8*4)+(7*1)+(6*5)+(5*3)+(4*0)+(3*3)+(2*4)+(1*1)=111
111 % 10 = 1
So 1415303-41-1 is a valid CAS Registry Number.
1415303-41-1Relevant articles and documents
N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG
-
Page/Page column 220, (2012/12/14)
The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
